SK282329B6 - 1,2,4-Triazolo[1,5-a]pyrimidíny, farmaceutická kompozícia s ich obsahom, spôsob ich prípravy a ich použitie - Google Patents

1,2,4-Triazolo[1,5-a]pyrimidíny, farmaceutická kompozícia s ich obsahom, spôsob ich prípravy a ich použitie Download PDF

Info

Publication number
SK282329B6
SK282329B6 SK437-96A SK43796A SK282329B6 SK 282329 B6 SK282329 B6 SK 282329B6 SK 43796 A SK43796 A SK 43796A SK 282329 B6 SK282329 B6 SK 282329B6
Authority
SK
Slovakia
Prior art keywords
triazolo
pyrimidine
ethyl
formula
compounds
Prior art date
Application number
SK437-96A
Other languages
English (en)
Slovak (sk)
Other versions
SK43796A3 (en
Inventor
David John Heal
Fernandez Mar�A Isabel Fernandez
Bruce Geremy Sargent
Original Assignee
Knoll Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Aktiengesellschaft filed Critical Knoll Aktiengesellschaft
Publication of SK43796A3 publication Critical patent/SK43796A3/sk
Publication of SK282329B6 publication Critical patent/SK282329B6/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
SK437-96A 1993-10-13 1994-10-12 1,2,4-Triazolo[1,5-a]pyrimidíny, farmaceutická kompozícia s ich obsahom, spôsob ich prípravy a ich použitie SK282329B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939321162A GB9321162D0 (en) 1993-10-13 1993-10-13 Therapeutic agents
PCT/EP1994/003364 WO1995010521A1 (en) 1993-10-13 1994-10-12 Therapeutic agents

Publications (2)

Publication Number Publication Date
SK43796A3 SK43796A3 (en) 1996-10-02
SK282329B6 true SK282329B6 (sk) 2002-01-07

Family

ID=10743505

Family Applications (1)

Application Number Title Priority Date Filing Date
SK437-96A SK282329B6 (sk) 1993-10-13 1994-10-12 1,2,4-Triazolo[1,5-a]pyrimidíny, farmaceutická kompozícia s ich obsahom, spôsob ich prípravy a ich použitie

Country Status (31)

Country Link
US (1) US5753665A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0723546B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH09503771A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1040537C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE188966T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU679573B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG62405B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9407812A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2173857A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ106996A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69422724T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0723546T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2142413T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI961630A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB9321162D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3032480T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUT74580A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL111259A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN179169B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY112110A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO306509B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ274500A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL177920B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT723546E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RO (1) RO117020B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2136684C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK282329B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW372237B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA42738C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1995010521A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA947949B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506382D0 (en) * 1995-03-29 1995-05-17 Boots Co Plc Pharmaceutical compositions
GB9507348D0 (en) * 1995-04-08 1995-05-31 Knoll Ag Therapeutic agents
US5714607A (en) * 1995-12-01 1998-02-03 American Cyanamid Company Process improvement in the synthesis of N- 3-(3-cyano-pyrazolo 1,5-a!pyrimidin-7-yl)phenyl!-N-ethylacetamide
EA002436B1 (ru) * 1996-07-25 2002-04-25 Мерк Шарп Энд Домэ Лимитед Замещенные производные триазоло-пиридазина в качестве лигандов рецепторов гамк
GB9617727D0 (en) 1996-08-23 1996-10-02 Knoll Ag Process
GB9626746D0 (en) * 1996-12-23 1997-02-12 Knoll Ag Process
DE19706336A1 (de) * 1997-02-19 1998-08-20 Basf Ag Verfahren zur Herstellung von enantiomerenreinen Alkoholen
DE19706337A1 (de) * 1997-02-19 1998-08-20 Basf Ag Verfahren zur Herstellung von enantiomerenreinen Estern
DE19707008A1 (de) 1997-02-21 1998-08-27 Basf Ag Verfahren zur Herstellung von enantiomerenreinen Alkoholen
DE69936998T2 (de) 1998-10-16 2008-05-21 Merck Sharp & Dohme Ltd., Hoddesdon Pyrazolotriazinderivate als gaba-rezeptorliganden
GB9906130D0 (en) * 1999-03-18 1999-05-12 Knoll Ag Compounds for use in therapy
GB9906126D0 (en) * 1999-03-18 1999-05-12 Knoll Ag Pharmaceutical formulations
GB9906124D0 (en) * 1999-03-18 1999-05-12 Knoll Ag Therapeutic agent
GB9914743D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
NZ523807A (en) * 2000-06-30 2004-09-24 Wyeth Corp Substituted-triazolopyrimidines as anticancer agents
TWI334868B (en) * 2003-06-03 2010-12-21 Nippon Kayaku Kk [1,2,4] triazoro [1,5-a] pyrimidine-2-ylurea derivative and use thereof
KR100783255B1 (ko) 2004-02-13 2007-12-06 워너-램버트 캄파니 엘엘씨 안드로젠 수용체 조절제
BRPI0509759A (pt) 2004-04-13 2007-10-16 Warner Lambert Co moduladores de androgênio
CA2562672C (en) 2004-04-22 2009-09-29 Warner-Lambert Company Llc 4-cyano-phenoxy derivatives as androgen modulators
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
BRPI0912928A2 (pt) 2008-08-29 2015-08-04 Concert Pharmaceuticals Inc "composto, e, composição isenta de pirogênio"
WO2010112485A1 (en) 2009-04-01 2010-10-07 Neurosearch A/S SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIMIDINES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS
US20120095025A1 (en) * 2009-04-01 2012-04-19 Neurosearch A/S SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIMIDINES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS
US8765770B2 (en) 2009-04-01 2014-07-01 Ataxion, Inc. Substituted [1,2,4]triazolo[1,5-a]pyrimidines and their use as potassium channel modulators
CN113874377A (zh) 2019-05-13 2021-12-31 埃科莱布美国股份有限公司 作为铜腐蚀抑制剂的1,2,4-三唑并[1,5-a]嘧啶衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE46306B1 (en) * 1977-02-11 1983-05-04 Ici Ltd Safeguarded toxic chemical compositions containing an emetic
FR2549834B1 (fr) * 1983-07-25 1985-10-18 Sanofi Sa Derives de triazolo-pyrimidine, leur procede de preparation et leur application therapeutique en tant que tonicardiaques
WO1989001478A1 (en) * 1987-08-07 1989-02-23 The Australian National University ARYLOXY- AND ARALKYLTHIO-IMIDAZO[1,2-b]PYRIDAZINES
US5387747A (en) * 1992-02-24 1995-02-07 Laboratoires Upsa Triazolopyrimidine derivatives which are angiotensin II receptor antagonists, their methods of preparation and pharmaceutical compositions in which they are present

Also Published As

Publication number Publication date
JPH09503771A (ja) 1997-04-15
CN1135754A (zh) 1996-11-13
IL111259A0 (en) 1995-03-30
AU679573B2 (en) 1997-07-03
CZ106996A3 (en) 1996-09-11
DE69422724T2 (de) 2000-09-07
NZ274500A (en) 1997-06-24
MY112110A (en) 2001-04-30
ATE188966T1 (de) 2000-02-15
BG100485A (bg) 1996-11-29
IN179169B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1997-09-06
RU2136684C1 (ru) 1999-09-10
GR3032480T3 (en) 2000-05-31
AU7855494A (en) 1995-05-04
NO961435D0 (no) 1996-04-11
BG62405B1 (bg) 1999-10-29
DE69422724D1 (de) 2000-02-24
EP0723546B1 (en) 2000-01-19
PL313970A1 (en) 1996-08-05
GB9321162D0 (en) 1993-12-01
US5753665A (en) 1998-05-19
ES2142413T3 (es) 2000-04-16
CN1040537C (zh) 1998-11-04
NO306509B1 (no) 1999-11-15
SK43796A3 (en) 1996-10-02
UA42738C2 (uk) 2001-11-15
PL177920B1 (pl) 2000-01-31
TW372237B (en) 1999-10-21
FI961630A7 (fi) 1996-04-12
DK0723546T3 (da) 2000-05-01
IL111259A (en) 1998-02-08
HUT74580A (en) 1997-01-28
ZA947949B (en) 1996-01-23
PT723546E (pt) 2000-04-28
BR9407812A (pt) 1997-05-06
WO1995010521A1 (en) 1995-04-20
NO961435L (no) 1996-06-10
EP0723546A1 (en) 1996-07-31
FI961630A0 (fi) 1996-04-12
RO117020B1 (ro) 2001-09-28
HU9600959D0 (en) 1996-06-28
CA2173857A1 (en) 1995-04-20

Similar Documents

Publication Publication Date Title
SK282329B6 (sk) 1,2,4-Triazolo[1,5-a]pyrimidíny, farmaceutická kompozícia s ich obsahom, spôsob ich prípravy a ich použitie
EP0820456B1 (en) 1,2,4-triazolo 4,3-b]pyridazine derivatives and their use
JP2003238418A (ja) 痛みの治療方法
EP1148881A1 (fr) UTILISATION DE DERIVES DE PYRIDAZINO [4,5-(b)]-INDOLE-1-ACETAMIDE POUR LA PREPARATION DE MEDICAMENTS DESTINES AUX MALADIES LIEES AU DYSFONCTIONNEMENT DES RECEPTEURS DE TYPE PERIPHERIQUE AUX BENZODIAZEPINES
CN101098867A (zh) 取代的亚砜类化合物和其制备方法及用途
WO1999002512A1 (en) Dl-2,3-diaryl-2h-1-benzopyrans
FR2476071A1 (fr) Nouveaux acides 2-amino-3-(a-hydroxybenzyl)-phenylacetiques et leurs esters et amides, utiles notamment comme agents anti-inflammatoires, et compositions pharmaceutiques les contenant
EP0626372B1 (fr) 2-Hydroxy-3-[1-(1H-imidazol-4-yl)alkyl]-benzènecarboximidamides pour le traitement du glaucome
FR2465733A1 (fr) Nouveaux derives imidazolylethoxymethyliques de 1,3-dioxoloquinoleines utiles notamment comme medicaments antibacteriens et antifongiques, leur procede de preparation et compositions therapeutiques et formes pharmaceutiques les contenant
WO2002007727A1 (fr) Utilisation de derives de pyridazino (4, 5) indole-1-acetamide pour la preparation de medicaments destines au traitement des pathologies liees aux dysfonctionnements des recepteurs de type peripherique aux benzodiazepines
CN100512809C (zh) 化合物在制备用于慢性移植排斥的药物中的用途
EP1218008A2 (en) New use of 1,2,4-triazolo[1,5-a]pyrimidines
JPS6112689A (ja) 環式アミド、その製法及び該化合物を含有する糖尿病及びガラクトース血症の合併症を治療又は予防するための製薬的組成物
JPS6038392B2 (ja) ナフチリジン誘導体およびその製造方法
WO2000056733A1 (en) Triazolopyrimidinol compounds and salts thereof
NZ248773A (en) 1,5,6,7-tetrahydro-4h-indazol-4-one compounds; analogues and medicaments
EP0511228A1 (en) Esters of 2-arylmethyl-1-naphthol derivatives as 5-lipoxygenase inhibitors